Drug Profile
Research programme: insulin-like growth factor-1 receptor antagonists - Antyra/Novo Nordisk
Alternative Names: ANT-429Latest Information Update: 22 Jan 2016
Price :
$50
*
At a glance
- Originator DGI Biotechnologies; Novo Nordisk
- Developer Antyra
- Class
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Pancreatic cancer
Most Recent Events
- 22 Jan 2016 No development reported - Preclinical for Cancer in USA (unspecified route)
- 22 Jan 2016 No development reported - Preclinical for Pancreatic cancer in USA (unspecified route)
- 14 Nov 2008 Preclinical trials in Cancer in USA (unspecified route)